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Superresolution Imaging Identifies 
That Conventional Trafficking 
Pathways Are Not Essential for 
Endoplasmic Reticulum to Outer 
Mitochondrial Membrane Protein 
Transport
Kyle Salka1, Shivaprasad Bhuvanendran1, Kassandra Wilson1, Petros Bozidis1,2, Mansi 
Mehta1, Kristin Rainey3, Hiromi Sesaki4, George H. Patterson3, Jyoti K. Jaiswal1,5 & Anamaris 
M. Colberg-Poley1,5,6
Most nuclear-encoded mitochondrial proteins traffic from the cytosol to mitochondria. Some of 
these proteins localize at mitochondria-associated membranes (MAM), where mitochondria are 
closely apposed with the endoplasmic reticulum (ER). We have previously shown that the human 
cytomegalovirus signal-anchored protein known as viral mitochondria-localized inhibitor of apoptosis 
(vMIA) traffics from the ER to mitochondria and clusters at the outer mitochondrial membrane (OMM). 
Here, we have examined the host pathways by which vMIA traffics from the ER to mitochondria and 
clusters at the OMM. By disruption of phosphofurin acidic cluster sorting protein 2 (PACS-2), mitofusins 
(Mfn1/2), and dynamin related protein 1 (Drp1), we find these conventional pathways for ER to the 
mitochondria trafficking are dispensable for vMIA trafficking to OMM. Instead, mutations in vMIA that 
change its hydrophobicity alter its trafficking to mitochondria. Superresolution imaging showed that 
PACS-2- and Mfn-mediated membrane apposition or hydrophobic interactions alter vMIA’s ability to 
organize in nanoscale clusters at the OMM. This shows that signal-anchored MAM proteins can make 
use of hydrophobic interactions independently of conventional ER-mitochondria pathways to traffic 
from the ER to mitochondria. Further, vMIA hydrophobic interactions and ER-mitochondria contacts 
facilitate proper organization of vMIA on the OMM.
Mitochondria consist of nearly a thousand proteins, and aside from the 13 proteins encoded by the mitochon-
drial genome, the rest are encoded by nuclear genes1. These proteins are synthesized in the cytosol and imported 
into mitochondria using highly conserved translocation machinery2. Analysis of the mitochondrial proteome 
has identified that a number of these proteins also localize in other organelles including over fifty proteins that 
are classified as endoplasmic reticulum (ER) proteins3. Cellular proteins that traffic to mitochondria via the 
ER include apoptosis inducing factor (AIF), acyl-CoA:diacylglycerol acyl-transferase 2 (DGAT2), and retinol 
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dehydrogenase 10 (Rdh10), which traffic directly from the ER to the mitochondria4–6. Aside from cellular proteins, 
pathogen-encoded proteins such as the human cytomegalovirus (CMV) encoded viral mitochondrial-localized 
inhibitor of apoptosis (vMIA), hepatitis c virus (HCV) encoded N3/4A protease, and human immunodeficiency 
virus 1 (HIV-1) encoded viral protein R (Vpr) also traffic from the ER to mitochondria7–12.
There are two routes proposed for protein trafficking from the ER to mitochondria. The first is based 
upon ER and the OMM proximity, where a bridge (tether) facilitates calcium (Ca2+) transfer through the 
mitochondria-associated membrane (MAM) calcium signaling complex, which contains inositol 1,4,5 trisphos-
phate receptors (IP3Rs), cytosolic glucose response protein 75 (Grp75) and the outer mitochondrial membrane 
(OMM)-localized voltage dependent anion channel (VDAC), and lipids between these compartments13–16. 
In yeast, MAM tethers, known as ER mitochondria encounter structure (ERMES) facilitate phospholipid 
exchange17. ER-OMM contacts may facilitate transfer of proteins between these compartments. In mammalian 
cells, several proteins including phosphofurin acidic cluster sorting protein 2 (PACS-2), Nogo (or reticulon 4) 
and mitofusins (Mfn1/2) have been implicated in regulating ER-mitochondrial apposition14,18–21. PACS-2 is 
required for proper distribution of the MAM-enriched protein calnexin22. It is currently debated whether mito-
fusins regulate ER-mitochondrial tethering and mitochondrial Ca2+ uptake in positive or negative manner. 
Although homotypic interactions between Mfn2 and heterotypic interaction with Mfn1 have been implicated 
in decreasing ER-mitochondria tethering and functional coupling23,24, a recent study re-established the previous 
report that Mfn2 is an ER-mitochondrial tether and its ablation reduces mitochondrial Ca2+ uptake without 
altering the mitochondrial Ca2+ uniporter complex21,25. While the precise mechanism of action of mitofusins 
in ER-mitochondria coupling is yet to be resolved, lack of Mfn1/2 has been shown to affect the distribution of 
proteins at the OMM by altered MAM tethering26. The second route for protein trafficking at the MAM involves 
vesicular transport from ER to mitochondria, where membrane scission protein called dynamin related protein 1 
(Drp1) facilitates transport of proteins from the ER to mitochondria4,10. Subpopulations of AIF and HIV-1 viral 
protein Vpr are packaged and transported to mitochondria in vesicles. Knockdown of Drp1, ATPase family AAA 
domain containing 3A (ATAD3A), or Mfn2 decreases AIF and HIV Vpr trafficking to mitochondria4,10. Drp1, 
ATAD3A and Mfn2 are suggested to play distinct roles by facilitating budding, movement and fusion of the ves-
icles, respectively.
Similar to the mitochondrial signal-anchored proteins, which traffic from the cytosol to the OMM, we found 
that CMV vMIA is signal-anchored by an N-terminal single pass hydrophobic leader that serves as part of its 
mitochondrial targeting signal (MTS)7,11. Rather than direct transport from the cytosol to the OMM, we pre-
viously showed that vMIA traffics sequentially from the ER to mitochondria through MAM contacts between 
the two organelles7–9,11. vMIA signal sequence is not cleaved through its trafficking to OMM, identifying that 
its transport does not involve transiting through the Golgi complex. However, the role of host proteins in vMIA 
trafficking has not yet been studied. Notably, vMIA targeting is efficient: vMIA is able to retarget a cellular ER 
protein, viperin, to mitochondria and the vMIA MTS can retarget the Tom20 hydrophobic leader to this ER to 
mitochondrial trafficking11,27. Thus, vMIA offers a valuable tool to define the mechanism for ER to mitochondrial 
trafficking of signal-anchored OMM proteins.
While no consensus MAM/mitochondrial targeting signal is known, the factors affecting trafficking at the 
MAM are now emerging11,22. Affinity for lipids has been implicated in MAM trafficking of proteins including 
the lipid synthetic proteins. Targeting of Rdh10 to the MAM and mitochondria requires its N- and C-terminal 
hydrophobic domains and Rdh10 can relocalize to lipid droplets6. Similarly, cellular retinol-binding protein type 
1 localizes to the MAM and mitochondria and can relocalize to lipid droplets6,28. Palmitoylation enriches cal-
nexin and thioredoxin related transmembrane protein in the MAM29. Sigma 1 receptor (Sig-1R) localizes to the 
MAM using cholesterol binding30,31. Similarly, the N-terminal MTS of vMIA contains an evolutionarily conserved 
hydrophobic leader, with a consensus cholesterol binding domain (CBD) and multiple basic residues and proline 
rich domain (PRD) downstream of the CBD7,11. We found that vMIA mutations that increase its MTS hydropathy 
score retarget vMIA to the secretory apparatus and reduce its mitochondrial trafficking11. Mutations in the vMIA 
CBD block its association with MAM lipid rafts, but do not affect its trafficking to the OMM32.
Similar to many other OMM proteins, including Tom20, Tom22, VDAC, and the associated cytosolic hexoki-
nase I33–35, vMIA also organizes in nanoscale clusters13,36. Using superresolution imaging by multifocal structured 
illumination microscopy (MSIM), gated stimulated emission depletion (gSTED) and photoactivated localization 
microscopy (PALM), we established that vMIA forms clusters of ~100–150 nm at the OMM of human cells13,36. 
Clustering has also been reported for inner mitochondrial membrane (IMM) proteins including mitochondrial 
inner membrane or cristae organizing system (MICOS or MINOS), and cytochrome C oxidase subunit 2 of com-
plex IV35,37. These mitochondrial protein clusters are not static as they can change in response to the functional 
requirements of mitochondria34, and following viral infection38. However, the cellular mechanism for facilitating 
clustering of mitochondrial proteins and how this is dynamically regulated is poorly understood.
In this study, we investigated the cellular mechanisms reported for ER to OMM protein trafficking and OMM 
clustering of a membrane-anchored protein. To test the requirements of ER-mitochondria apposition and tether-
ing (bridge model) for trafficking, we used PACS-2 null and Mfn1/2 null mouse embryonic fibroblasts (MEFs)39,40 
and PACS-2 knockdown human cells. To investigate the role of membrane scission (vesicle model) in traffick-
ing from ER to mitochondria, we used Drp1-null cells41. Additionally, by using vMIA MTS mutants, we have 
assessed the role of hydrophobic and lipid interactions on mitochondrial localization of vMIA and its ability to 
dimerize and form clusters at the OMM. Our results identify that vMIA uses an unconventional hydrophobic 
interaction-mediated mechanism to traffic from the ER to the OMM and does not require Drp1-, PACS-2-, and 
mitofusin-mediated pathways. Instead, PACS-2 and Mfn-mediated ER-mitochondria apposition regulates the 
ability of vMIA to form clusters at the OMM.
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Results
vMIA traffics to and clusters at the OMM in MEFs. vMIA traffics from the ER to OMM in human cells 
including human primary fibroblasts (HFFs), U373 and HeLa cells7–9,11,13,36. By using confocal microscopy and 
gSTED superresolution microscopy of vMIA with the OMM marker Tom20, we investigated the localization 
of vMIA at the OMM in human and mouse cells. Confocal microscopy confirmed mitochondrial localization 
of vMIA in all (human and mouse) cells tested (Fig. 1a). Pixel co-localization analysis in WT-MEFs identified 
83.9 ± 0.5% co-localization between vMIA and Tom20 (Fig. S1), showing that, similar to the human primary 
fibroblasts, vMIA traffics efficiently to the OMM in WT MEFs.
Using gSTED superresolution imaging, we examined if the vMIA clusters that we previously described in the 
human cells13,36 localize with Tom20 clusters. Using HeLa cells, we found that vMIA exists in clusters that can 
include or exclude Tom20 clusters (Fig. 1b inset, and corresponding line intensity profile in 1c). Use of gSTED 
imaging together with MSIM superresolution imaging of the wild type (WT) MEFs showed that vMIA also 
formed clusters at the OMM in mouse cells (Fig. 1d–g). MSIM analysis of vMIA clustering at the OMM in MEFs 
identified that the full width half maximum (FWHM) of vMIA clusters is 179.9 ± 3.7 nm (n = 75) (Fig. 1c,d). This 
size is similar to 100–150 nm sized clusters we previously detected in the human cells13,36. Together, above results 
identify that vMIA mitochondrial trafficking and organization in clusters at the OMM occurs similarly in human 
and mouse cells.
Figure 1. vMIA traffics to and clusters at the OMM in mouse embryonic fibroblasts. (a) Human (HFF and 
HeLa) and mouse (MEF) fibroblasts were transfected transiently (19 hours) to express vMIA-EYFP and then 
immunolabeled for the OMM marker Tom20. The images show an optical slice obtained by deconvolution of 
a confocal z-stack. (b) A single optical plane from deconvolved z-stack of gSTED images showing clustered 
distribution of vMIA-EYFP and Tom20 (immunostained) on the OMM of a HeLa cell transfected as above. 
Zoom shows the merged image marked by white box in the merged channel. (c) Normalized intensity profile of 
the red and green pixels marked by the dotted line in the zoomed region in panel b. (d) Single optical plane from 
deconvolved z-stack of gSTED images showing clustered distribution of vMIA-EYFP on the OMM in a WT 
MEF. Zoom shows the region marked by white box. (e) A single plane from an MSIM z-stack images showing 
clustered distribution of vMIA-EGFP on the OMM of a transfected MEF cell. Zoom of a single mitochondrion 
(boxed) shows vMIA clustering and line marks the region used to plot the intensity profile in the panel d. (f) 
Normalized intensity profile of the mitochondrion along the pixels marked by the solid line in the zoomed 
region. (g) Plot showing vMIA cluster size (FWHM) in WT MEFs. The line in the box and red, cross mark 
indicate the median (177.0) and mean (179.9 ± 3.7), respectively (n = 75).
www.nature.com/scientificreports/
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vMIA forms homodimers in MEFs. vMIA is known to homodimerize during ER to mitochondrial traf-
ficking in human (HFFs and HeLa) cells42,43. To monitor this process in mouse cells, we imaged live cells using 
fluorescent lifetime imaging microscopy (FLIM) (Fig. 2). As has been demonstrated before, homoFRET imaging 
allows monitoring protein-protein proximity by change in fluorescence lifetime44. We thus imaged EGFP lifetime 
in WT MEFs expressing cytosolic EGFP or vMIA-EGFP. This shows a homogenously greater pixel lifetimes in 
cell expressing EGFP (Fig. 2a,b), but a more heterogeneous pixel lifetime values in a cell expressing vMIA-EGFP 
(Fig. 2c,d). Quantification of lifetime of the pixels (e.g.: those marked by the circles in Fig. 2a,c) showed the 
average lifetime of cytosolic EGFP was 3.41 ± 0.01 ns (10 regions per cell, n = 14 cells), which was reduced to 
3.10 ± 0.01 ns for vMIA-EGFP (10 regions per cell, n = 13 cells, p < 0.0001) (Fig. 2e). This decrease in EGFP life-
time when tagged to vMIA demonstrates that, similar to human cells, vMIA efficiently homodimerizes during its 
trafficking from ER to mitochondria in MEFs. The quantitative nature of FLIM also provides an assay to quantify 
alterations in vMIA homodimerization on a single cell basis. We have used this ability in subsequent sections to 
study the effects of various genetic changes in host cells and in vMIA itself on its ability to form homodimers.
Mfn2 affects vMIA clustering at the OMM. Mfn1/Mfn2 are proposed to tether the ER to mitochon-
dria21,25, and interaction of vMIA with Mfn2 is important for its anti-apoptotic function45. Thus, we hypothesized 
that mitofusin-vMIA interactions may regulate vMIA trafficking from ER to OMM. To test this, we first examined 
vMIA and Mfn2 colocalization in MEFs (Fig. 3). In MEFs, Mfn2 localizes at mitochondrial junctions, causing 
Mfn2-YFP (green) to localize with the OMM marker, Tom20-mCherry (red) (89 ± 3.4%) (Fig. 3a). However, 
unlike Tom20, Mfn2 forms discreet puncta at the mitochondrial junction sites, causing only a small percentage 
Figure 2. Use of fluorescence lifetime imaging to monitor vMIA homodimerization in WT MEFs. vMIA-
EGFP was transiently expressed (as above) in WT MEFs, and live cells were imaged by using frequency 
domain lifetime microscopy. (a) Fluorescent lifetime image of a WT MEF expressing cytosolic EGFP. The 
pixels are pseudocolored based on their lifetime values as indicated by the heat map scale. (b) Fluorescence 
lifetime polar plot representing the frequency characteristics of each pixel in the ROI marked by the white 
circle in panel a. The colored squares represent a unique pixel lifetime and the red square marks the median 
lifetime value of the ROI (c) Fluorescent lifetime image of a WT MEF expressing vMIA-EGFP. The pixels are 
pseudocolored based on their lifetime as in panel b. (d) Polar plot presentation of the fluorescence lifetime of 
the ROI marked by white circle in panel c. The plot coordinates for (b) and (d) are x = M cosφ and y = M sinφ, 
where M is the modulation and φ is the phase delay. (e) The fluorescence lifetime comparison of cytosolic EGFP 
(τ = 3.41 ± 0.01 ns, n = 140 ROIs from 14 cells) and vMIA-EGFP (τ = 3.10 ± 0.01 ns, n = 130 ROIs from 13 cells) 
in WT MEFs. ****Represents p < 0.0001.
www.nature.com/scientificreports/
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Figure 3. Expression of vMIA causes redistribution of Mfn2 on the OMM. MEFs transfected with Mfn2-YFP 
(pseudocolored green) and Tom20-mCherry (red), (a) without or (b) with vMIA-CFP (blue) were analyzed 
by confocal microscopy. (a) In MEFs not expressing vMIA, Mfn2 shows punctate distribution along the 
mitochondria; boxes mark the zoomed regions shown below. (b) Expression of vMIA causes Mfn2 to distribute 
more uniformly along the mitochondria; boxes mark the zoomed regions below. (c) Plot showing quantification 
of Mfn2 colocalization with OMM marker Tom20 in MEFs expressing or not expressing vMIA-CFP. The line 
in the box represents the median value of cells not expressing (13%) or expressing vMIA (73.9%) (n > 16 cells). 
***Represents p < 0.001.
www.nature.com/scientificreports/
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of Tom20 pixels (18 ± 4.1%) at the OMM to overlap with the Mfn2 pixels (Fig. 3c). Expression of vMIA in MEFs 
caused redistribution of Mfn2 along the mitochondria (Fig. 3b). While the punctate distribution of Mfn2 was 
still detectable, Mfn2 redistributed along the entire OMM such that colocalization of Tom20 pixels with Mfn2 
increased from 18 ± 4.1% to 75 ± 5.1% (Fig. 3b,c). Mfn2 also colocalized well with vMIA (85 ± 3.4%; Fig. 3b).
In view of the redistribution of Mfn2 upon vMIA expression, we investigated whether mitofusins affect vMIA 
trafficking. The two mitofusin proteins (Mfn1 and Mfn2) have been shown to be partly redundant, as overexpres-
sion of either protein is able to rescue the loss of the other46. In view of this partial redundancy in the function of 
the mitofusins, to test if Mfn2 is required for vMIA trafficking from the ER to OMM, we made use of Mfn1/2-null 
MEFs (Fig. 4). Similar to the extensive colocalization of vMIA-CFP with Tom20-mCherry in WT MEFs 
(83.9 ± 0.5%; Fig. S1), vMIA colocalized with Tom20-mCherry even in the Mfn1/2-null MEFs (85.8 ± 1.4%) 
(Fig. 4a, Fig. S1). This shows that vMIA can traffic normally to mitochondria even in the absence of Mfn1 and 
Mfn2, and show that mitofusins are not required for vMIA trafficking to the OMM. FLIM analysis of vMIA-EGFP 
in Mfn1/2-null MEFs showed that vMIA-EGFP lifetime in Mfn1/2-null MEFs (τ = 3.10 ± 0.01 ns, n = 13) was 
significantly lower than the lifetime of cytosolic EGFP (τ = 3.46 ± 0.02 ns, n = 15, p < 0.0001) (Fig. 4b), and was 
similar to that of the WT-MEFs (Fig. 2). Thus, lack of mitofusins does not affect vMIA homodimerization.
Similar to our previous observation in primary HFFs and human cell lines13,36 and herein in MEFs (Fig. 1b,c), 
superresolution imaging by MSIM showed that vMIA is organized in nanoclusters at the OMM even in the 
Mfn1/2-null MEFs (Fig. 4c). Compared to the density of vMIA clusters at the OMM in WT MEFs (0.8 ± 0.05 clus-
ters/µm, n = 50 mitochondria), Mfn1/2-null MEFs showed a 38% increase in the number of clusters (1.1 ± 0.05 
clusters/µm/mitochondria, n = 40 mitochondria; p = 0.0005) (Fig. 4d, Fig. S2). Using MSIM imaging, we meas-
ured if this increase in the number of vMIA clusters affected the vMIA cluster size. This showed that despite 
the increased number of clusters/mitochondria, the vMIA cluster size was unaltered between the WT MEFs 
(179.9 ± 3.7 nm, n = 75 clusters) and Mfn1/2-null MEFs (177.1 ± 3.7 nm, n = 60) (Fig. 4e,f, Fig. S2). We found 
no difference in the percentages of mitochondria with clustered vMIA between the WT (91 ± 5.6%, n = 5) and 
Figure 4. Role of mitofusins (Mfn1/2) on vMIA trafficking and clustering on mitochondria. (a) Mfn1/2-null 
MEFs were transiently transfected to express vMIA-CFP (pseudocolored green) and Tom20-mCherry (red) and 
imaged by confocal microscopy. The images show a single confocal plane from a deconvolved z-stack presented 
as monochrome images of the individual channels, which are pseudocolored for the merged image, and the 
boxed region marks the region zoomed in the inset. (b) The fluorescence lifetime comparison of cytosolic EGFP 
(τ = 3.46 ± 0.015 ns, n = 150 regions from 15 cells) and vMIA-EGFP (τ = 3.10 ± 0.011 ns, n = 130 regions from 
13 cells) in Mfn1/2-null MEFs. (c) A single plane from an MSIM z-stack images showing clustered distribution 
of vMIA-EGFP on the OMM of an Mfn1/2-null MEF. A zoom of mitochondria shows vMIA clustering. (d) The 
number of vMIA clusters/µm of the OMM in WT MEFs (n = 50) and Mfn1/2-null MEFs (n = 40) are shown. (e) 
Normalized intensity profile along the solid line shown in the zoomed inset in panel c. (f) The FWHM of vMIA 
clusters (n = 40) in Mfn1/2-null MEFs were measured and plotted. The line and red cross mark indicate the 
median and mean, respectively. ****Represents p < 0.0001.
www.nature.com/scientificreports/
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Mfn1/2-null MEFs (87.5 ± 3.2%, n = 4) (Fig. S2). Thus, mitofusins are dispensable for the ability of vMIA to traffic 
to the OMM, and to homodimerize and form clusters at the OMM. However, the presence of mitofusins prevents 
the formation of excessive vMIA clusters at the OMM. An alternative possibility is that the increase in density of 
vMIA clusters at the OMM in Mfn1/2-null cells reflects the alteration of OMM protein distribution caused by the 
absence of mitofusins26.
PACS-2 alters vMIA clustering without affecting vMIA trafficking to the OMM. Another regula-
tor of ER mitochondrial apposition is PACS-218. Therefore, we examined if PACS-2-mediated ER-OMM appo-
sition is required for vMIA trafficking from the ER to OMM. We tested the ability of vMIA-EGFP to traffic to 
the OMM in PACS-2-null MEFs. Transfection of control WT MEFs with vMIA-mCherry and PACS-2-EGFP 
showed that vMIA-labeled (red) mitochondria are interspersed between PACS-2-labeled (green) ER (Fig. 5a). 
vMIA-mCherry and PACS-EGFP distributed similarly in HFFs (Fig. S3). Similar to the WT MEF, vMIA-EGFP 
Figure 5. Role of PACS-2 in vMIA trafficking and clustering on the mitochondria. (a) WT MEFs transiently 
expressing vMIA-mCherry (red) and PACS-2-EGFP (green) were imaged by confocal microscopy. Shown are 
single confocal planes from a deconvolved z-stack as monochrome images of individual channels, which are 
pseudocolored for the merged image. The box marks the zoomed region. (b) A single confocal plane from a 
deconvolved z-stack of confocal images of PACS-2-null MEFs transiently expressing vMIA-EGFP (green) and 
Tom2-mCherry (red). The monochrome image of each fluorophore and the merged images are shown. The 
box marks the zoomed area. (c) The fluorescence lifetime comparison of cytosolic EGFP (τ = 3.44 ± 0.009 ns, 
n = 150 regions from 15 cells) and vMIA-EGFP (τ = 3.08 ± 0.009 ns, n = 120 regions from 12 cells) in 
PACS-2-null MEFs. (d) Zoomed single optical plane of a mitochondrion from a MSIM z-stack showing 
clustered distribution of vMIA-EGFP on the OMM of a transfected PACS-2-null MEF. (e) The percentage of 
mitochondria (20 mitochondria/cell) with clustered vMIA along the OMM in WT MEFs (n = 5 cells) and 
PACS-2-null MEFs (n = 6 cells). (f) Normalized pixel intensity of vMIA-EGFP along the line shown in the 
zoomed d inset. (g) Box plot showing the FWHM distribution of vMIA clusters (n = 60 clusters) in WT MEFs 
and PACS-2-null MEFs. The line and red, cross mark indicate the median and mean, respectively. (h) HeLa 
(PSS-120) cells8 were lipofected with nonspecific (NS siRNA) or PACS-2 (PACS-2 siRNA) siRNAs and vector 
expressing WT vMIA and harvested 48 h later as described18. PACS-2 knockdown was assessed using rabbit 
anti-PACS-2 antiserum (1:500; gift from Dr. G. Thomas). Transfected cells were fractionated to obtain purified 
microsomes and mitochondria. 10 μg of fractionated proteins were separated by SDS-PAGE and analyzed by 
Western using anti-vMIA (DC35, 1:500)8 or mitochondrial (Grp75, 1:1000; Stressgen) marker. Monomeric and 
dimeric vMIA are indicated by the grey and open arrows, respectively. *Represents p < 0.05, ****represents 
p < 0.0001. The blots were cropped to enhance the conciseness of presentation. Full-length blots are presented 
in Supplementary Figure S5.
www.nature.com/scientificreports/
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and Tom20-mCherry colocalized extensively in the PACS-2 null MEFs (88.4 ± 1.0%, n = 11 cells) (Figs 1a and 5b, 
Fig. S1). However, vMIA distributed more diffusely along the OMM in PACS-2-null MEFs, which increased colo-
calization of vMIA with Tom20 in PACS-2 null cells to 88.4 ± 0.8% (n = 11 cells) as compared to 83.9 ± 0.5% colo-
calization in the WT MEFs (p = 0.0006). This shows that vMIA traffics efficiently to mitochondria in PACS-2-null 
MEFs. FLIM analysis of vMIA-EGFP in PACS-2 null MEFs showed vMIA-EGFP lifetime of 3.08 ± 0.01 ns (n = 12 
cells) in PACS-2-null MEFs, is similar to that in the WT MEF (τ = 3.10 ± 0.01) and is significantly lower than the 
corresponding PACS-2-null cells expressing cytosolic EGFP (τ = 3.44 ± 0.01 ns, n = 15 cells, p < 0.0001) (Fig. 5c).
By MSIM imaging of vMIA-EGFP in PACS-2-null MEFs, we found that while mitochondria with clustered 
vMIA can be detected (Fig. 5d), the percentage of such mitochondria with clustered vMIA (60.8 ± 7.5%, n = 6 
cells) was lower than in WT MEFs (91.0 ± 5.7%, n = 5 cells, p = 0.04) (Fig. 5e, Fig. S2). These results show that 
vMIA’s ability to form clusters at the OMM is reduced by the reduced apposition between ER and OMM due to 
the lack of PACS-2. Concomitantly, the size (FWHM) of vMIA clusters was significantly larger in PACS-2-null 
MEFs (190.9 ± 3.7 nm, n = 60 mitochondria) as compared to the WT MEFs (179.9 ± 3.7 nm, n = 75 mitochon-
dria, p = 0.02) (Fig. 5f,g, Fig. S2). However, the number of vMIA clusters/mitochondria was not different between 
the PACS-2-null (0.8 ± 0.05 clusters/µm) and WT MEFs (0.8 ± 0.06 clusters/µm) (Fig. S2). Together, above results 
with Mfn-null and PACS-2-null MEFs validate the importance of ER-OMM tethering on proper distribution and 
clustering of vMIA at the OMM.
To further verify the effects of PACS-2 on organization of vMIA at mitochondria, we used siRNA to 
knockdown PACS-2 in human (HeLa) cells (Fig. 5h). Using these cells transfected with vMIA and the biochemical 
fractionation approach we have developed to monitor ER to mitochondrial trafficking, we examined the role 
of PACS-2 in vMIA trafficking in human cells (Fig. 5h). Use of ER resident enzyme DPM1 and mitochondrial 
protein Grp75 as markers for ER and mitochondria, respectively, we verified the identity of these two fractions. 
As expected we observed vMIA in ER and mitochondrial fractions (Fig. 5h, filled arrow) and also observed vMIA 
dimers (Fig. 5h, open arrow). However, while vMIA monomers were also present in the ER and mitochondria 
fractions of PACS-2 depleted cells, the dimeric form was only detected in the mitochondrial fraction of cells 
treated with nonspecific siRNA but not with PACS-2 siRNA. These results independently validate our findings 
by superresolution imaging of the PACS-2 null MEFs that PACS-2 is not required for vMIA trafficking to the 
mitochondria, but is required for dimerization and proper organization of vMIA at the mitochondria. Use of 
both Mfn1/2-null and of PACS-2 null cells offers no evidence to support the bridge model for vMIA protein 
trafficking from ER to the mitochondria. Thus, we next tested the Drp1-mediated vesicular trafficking model for 
the ER-mitochondrial protein transport.
Drp1 does not regulate vMIA trafficking and its clustering at the OMM. Drp1 is known to asso-
ciate with the ER and facilitate its normal morphology20,47, but its role in regulating vMIA-induced change in 
mitochondrial morphology has been debated48,49. However, Drp1 has been implicated in vesicular trafficking 
of AIF and Vpr from the MAM to mitochondria4,10. To test if Drp1 may facilitate vesicle-mediated trafficking of 
vMIA between ER and mitochondria, we used Drp1-null MEFs41. Using cells transfected with vMIA-CFP and 
mCherry-Drp1, we observed these two markers to colocalize in HFFs (mean, 65.9 ± 4.2%, n = 13 cells) and in WT 
MEFs (Fig. 6a, Figs S1 and S3). In Drp1-null MEFs, we observed efficient trafficking of vMIA to the mitochondria 
as shown by extensive colocalization of vMIA-CFP with Tom20-YFP (82.5 ± 2.8%, n = 11 cells) (Fig. 6b), which 
is similar to the WT MEFs (83.9 ± 0.5%) (Fig. S1). Thus, vMIA can traffic efficiently to mitochondria even in the 
absence of Drp1-mediated vesicular trafficking between ER and mitochondria. FLIM analysis of vMIA-EGFP 
showed that the lack of Drp1 did not affect the ability of vMIA to homodimerize (Fig. 6c) - vMIA-EGFP lifetime 
(τ = 3.04 ± 0.03 ns, n = 13 cells) was significantly lower than the cytosolic EGFP (τ = 3.40 ± 0.01 ns, n = 12 cells, 
p < 0.0001), and no different from that of vMIA-EGFP lifetime in WT MEFs (Fig. 2e).
MSIM imaging of vMIA-EGFP demonstrated the ability of vMIA to form clusters at the OMM in Drp1 null 
cells (Fig. 6d–f). These vMIA-EGFP clusters in Drp1-null cells were similar in size (172.1 ± 2.8 nm; n = 100 mito-
chondria) to those observed in WT MEFs (179.9 ± 3.7 nm; n = 75 mitochondria) (Fig. 6e,f, Fig. S2). Compared 
to the WT MEFs, lack of Drp1 affected neither the number of vMIA clusters/µm (0.8 clusters/µm/mitochondria) 
nor the percentage of mitochondria with clustered vMIA (100 ± 0%) (Fig. S2). Thus, by all the measures used, 
we found that lack of Drp1-mediated vesicle trafficking did not affect the ability of vMIA to traffic from ER to 
mitochondria, dimerize, or properly cluster at the OMM.
Lipid and hydrophobic interactions reduce vMIA dimerization and clustering at the OMM. 
Above results identify that protein-mediated ER-OMM tethering regulates the ability of vMIA to form clusters at 
the OMM, but does not affect ER to OMM protein trafficking. Through the use of two vMIA mutants that have 
leader sequence with higher hydrophobicity - high hydrophobicity A (HHA) and B (HHB) mutants we have 
previously identified that hydrophobic interactions of vMIA affect its trafficking to the mitochondria11. Between 
the vMIA hydrophobicity mutants, HHA and HHB, it is the HHB mutant that has larger hydropathy score of its 
N-terminal leader (residues 1–22)11. In contrast, the vMIA cholesterol binding domain II (CBDII) mutant has 
a mutant cholesterol binding domain (residues 14–23), which reduces its association with the MAM lipid rafts, 
without affecting trafficking to the OMM32. Using these two vMIA mutants with defects in lipid binding proper-
ties and divergent trafficking fates, we assessed if altered lipid interactions affect vMIA’s ability to homodimerize 
and form clusters.
Using FLIM, we assessed the ability of vMIA and its mutants to homodimerize. Compared to the WT 
vMIA-EGFP (τ = 3.10 ± 0.01 ns), lifetimes of both the mutant vMIA-EGFP were increased - vMIA-CBDII-EGFP 
(τ = 3.14 ± 0.01 ns; p = 0.003) and vMIA-HHB-EGFP (τ = 3.2 ± 0.01 ns; p < 0.0001) (Fig. 7g). Using MSIM 
imaging, we readily detected clustering of WT vMIA and of vMIA CBDII at the OMM (Fig. 7a and b, Fig. S4). 
In contrast, vMIA HHB mutant localized away from the mitochondria, on the ER and did not form clusters 
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(Fig. 7c). Further, compared to WT vMIA, which formed clusters on 88.0 ± 3.7% (n = 5 cells) mitochondria, 
vMIA CBDII mutant formed clusters in fewer mitochondria (71.7 ± 4.8%, n = 6 cells; p = 0.03) (Fig. 7d). Despite 
the reduced homodimerization and reduction in the number of mitochondria with vMIA-CBDII clusters, neither 
the vMIA-CBDII cluster sizes (Fig. 7e) nor the cluster density per mitochondria (Fig. 7f) were different from WT 
vMIA. Together, these results show that lipid and other hydrophobic interactions facilitate ER-OMM trafficking 
and the nanoscale organization of vMIA at the OMM.
Discussion
Through the use of multiple available MEF knockout cell lines, we have performed a comprehensive analysis of 
ER-mitochondrial trafficking and OMM organization of signal-anchored viral protein vMIA. Our approach of 
using a combination of mouse (MEFs) and human (HeLa cells and HFFs) cells to study vMIA trafficking is based 
upon the previous findings from multiple laboratories that vMIA traffics efficiently and similarly in these CMV 
permissive and non-permissive cells7–9,11,13,27,32,36,43,50,51. Furthermore, most of vMIA functions (including mito-
chondrial fragmentation, actin rearrangement, host cell protein retargeting to mitochondria, metabolic effects, 
inhibition of ATP synthesis, and inhibition of antiviral signaling) are unaffected by the cell being permissive or 
not to CMV growth27,43,51. Our results herein show that Mfn1, Mfn2, and PACS-2-mediated ER-mitochondria 
tethering is not required for ER-mitochondria trafficking. Instead, we show that these proteins facilitate cluster-
ing of proteins at the OMM. Further, we find that lack of Drp1 does not affect ER to mitochondrial trafficking 
Figure 6. Role of Drp1 on vMIA trafficking and clustering on the mitochondria. (a) HFFs were lipofected 
with vectors expressing vMIA-CFP (pseudocolored green) and mCherry-Drp1 (red)57. Cells were imaged by 
confocal microscopy and single slice of the deconvolved images is shown as monochrome and pseudocolored 
images as above. (b) Confocal image of a Drp1-null MEF transiently expressing vMIA-CFP (pseudocolored 
green) and Tom20-YFP (pseudocolored red). Monochrome images show the individual channels and the 
merged image demonstrates vMIA colocalization with Tom20-YFP. A zoom of the boxed region of interest 
is shown. (c) The fluorescence lifetime comparison of cytosolic EGFP (τ = 3.40 ± 0.013 ns, n = 120 regions 
from 12 cells) and vMIA-EGFP (τ = 3.04 ± 0.026 ns, n = 130 regions from 13 cells) in Drp1-null MEFs. (d) A 
single plane from an MSIM z-stack images showing clustered distribution of vMIA-EGFP on the OMM of a 
transfected Drp1-null MEF. A zoom of a single mitochondrion shows vMIA clustering. (e) Normalized pixel 
intensities of a line shown along the mitochondrion in inset of panel d. (f) Box plot showing the distribution of 
vMIA clusters (n = 40 cells) in WT MEFs and Drp1-null MEFs. ****Indicates p < 0.0001.
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or OMM clustering of vMIA. While Drp1 has been implicated in vesicle mediated trafficking between ER and 
mitochondria4,10, it is conceivable that lack of Drp1 resulting in elongated mitochondria may also impact on 
ER-mitochondria tethering. However, our observation that Drp1 deletion did not affect vMIA trafficking or clus-
tering at the mitochondria suggests a potential role of Drp1 in mediating ER-mitochondria tethering is also 
not relevant for vMIA trafficking or clustering at the OMM. Mfn1/2 and PACS-2 have been shown to maintain 
ER-mitochondria apposition18,21.
vMIA interacts with Mfn245, while PACS-2 is known to alter subcellular distribution of the cellular MAM 
protein calnexin22. Despite these results suggesting a potential involvement of Mfn1/2 and PACS-2 in vMIA traf-
ficking from the ER to mitochondria, we find this is not the case. We thus envision that vMIA may traffic to mito-
chondria by multiple, parallel pathways for trafficking from the ER to mitochondria, such that knock out of any 
one pathway does not inhibit its trafficking but affects its optimal organization at the OMM. Alternatively, vMIA 
may traffic by a pathway that is independent of ER-mitochondrial tethering by PACS-2 and Mfn2 and of vesicle 
formation by Drp1. Such a pathway may use lipid affinity or a cytosolic lipid transport protein to translocate 
without vesicular or bridging requirements. It was recently found that phosphatidylserine (PS) transport from the 
ER to mitochondria does not require proteinaceous linkers between the organelles but a cytosolic protein, VAT-1, 
which has affinity for PS52. In favor of such a mode of trafficking, we found that vMIA mutant that has increased 
hydropathy fails to traffic to the OMM11.
vMIA’s ability to translocate to the lipid-synthetic rich MAM subdomains potentially enables it to usurp lipid 
trafficking pathways. Association with lipids is known to enable some proteins to target the MAM. For example, 
Sig-1R protein utilizes cholesterol affinity to associate with the MAM31. Palmitoylation enriches calnexin and 
TMX in the MAM29. Indeed, lipid association appears to enable vMIA trafficking from the MAM to mitochon-
dria. We found that the vMIA HHA and HHB mutants, which have increased hydrophobicity of the N-terminal 
Figure 7. Analyses of vMIA HHB and CBDII mutant clustering by MSIM and FLIM. HeLa cells were 
transiently transfected with vectors expressing (a) vMIA-EGFP, (b) vMIA-CBDII-EGFP or (c) vMIA-HHB-
EGFP (green) as previously described36. The cells were co-transfected with only a mitochondrial marker (Mito-
BFP, blue) (a,b), or with Mito-BFP and an ER marker (ER-RFP, red) (c). Cells were fixed and a single plane from 
an MSIM z-stack image showing distribution of vMIA-EGFP and mitochondrial and ER marker is shown. A 
zoom of regions marked by the white boxes in each image is shown below. (d) The percentages of mitochondria 
with clustered vMIA in HeLa cells expressing vMIA-EGFP (88.0 ± 3.7%, n = 5 cells) or vMIA-CBDII-EGFP 
(71.7 ± 4.8%, n = 6 cells). (d) The size of vMIA (mean 169.18, min: 110, median 167, max: 233, n = 50) and 
vMIA-CBDII (mean 164.55, min: 111, median 159, max: 230, n = 60) clusters were determined. p = 0.4024. The 
lines and red crosses indicate the medians and means, respectively. (f) The number of vMIA clusters in HeLa 
cells expressing vMIA-EGFP (mean 0.638, min: 0.194, median 0.562, max: 1.73, n = 50) or vMIA-CBDII-EGFP 
(mean = 0.563, min: 0.153, median 0.526, max: 1.312, n = 60) were determined (p = 0.3118). The line and 
red, cross mark indicate the median and mean, respectively. (g) vMIA-HHB and vMIA-CBDII are defective 
in dimerization as measured by FLIM. Shown are the fluorescence lifetime comparisons of vMIA-EGFP 
(τ = 3.10 ± 0.009 ns), vMIA-CBDII-EGFP (τ = 3.14 ± 0.007 ns) and vMIA-HHB-EGFP (τ = 3.2 ± 0.008 ns). 
*Represents p < 0.03, **represents p < 0.003, ****represents p = 0.0001.
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leader, are retargeted to the secretory apparatus and are less efficient in mitochondrial trafficking11. These results 
suggest that vMIA’s targeted association with lipids in the ER/MAM subdomain, in part, underlies its ability to 
translocate to the OMM. In addition, other vMIA MTS elements, including modification of its 21SY motif and 
downstream proline rich domain (33PLPP), regulate its trafficking to the OMM11. Nonetheless and in contrast 
to Sig-1R, vMIA targeting to the MAM and mitochondria is not mediated by cholesterol binding. vMIA CBD 
mutants, defective in cholesterol binding, traffic efficiently from the MAM (but not to the MAM lipid rafts) to 
mitochondria32. Once in the MAM lipid synthetic enriched sub-domain, we suggest that vMIA could use a cyto-
solic lipid carrier to translocate to the OMM as has been shown for PS trafficking from the outer to inner leaflet of 
the mitochondrial membrane, by the cytosolic protein VAT-152.
Following trafficking to the mitochondria, vMIA forms nanometric clusters in the OMM13,36. This organ-
ization of vMIA clusters at the OMM is similar to that of multiple mitochondrial proteins33,35,37. However, the 
mechanism underlying clustering of these proteins has not been addressed. Our results show that Drp1 does not 
affect the ability of vMIA to homodimerize, but PACS-2 and mitofusins are needed for proper distribution and 
clustering of vMIA at the OMM. The density of vMIA clusters at the OMM appears to be negatively regulated by 
Mfn1/2 such that in their absence, more vMIA clusters are localized in the OMM. This may result from vMIA’s 
ability to interact with Mfn1/245. Herein, we documented that vMIA redistributes Mfn2 at the OMM. This inter-
action with and redistribution of Mfn2 may exclude interactions with cellular proteins present in vMIA clusters 
and thereby reduce vMIA clustering in presence of Mfn1/2. In contrast, the absence of PACS-2 reduces the per-
centage of mitochondria with clustered vMIA. As PACS-2 regulates apposition of the ER and OMM, its presence 
may enhance the number of MAM contact sites which may, in turn, affect vMIA distribution and clustering in 
OMM subdomains close to the MAM tethering sites.
Emerging evidence suggests that mitochondrial lipids can modulate the organization and distribution of some 
mitochondrial nanoscale complexes - low ergosterol content of yeast mitochondrial membranes for targeting of 
some OMM proteins with C-terminal anchors53. Consistent with this, we find that the cholesterol binding mutant 
of vMIA (CBD II) reduced the number of mitochondria with clustered vMIA. Moreover, in addition to sterol, the 
mitochondria specific lipid cardiolipin has been shown to be required for the localization of yeast Mic27/Mic10/
Mic12 sub-complex at cristae junctions in the inner mitochondrial membrane54. These roles of lipids suggest the 
possibility that the lipid composition of the MAM and of the OMM facilitate ER to mitochondrial trafficking of 
vMIA through association with its leader sequence. Our work highlights the need to study the role of lipids in 
ER-mitochondria targeting and OMM organization of proteins.
Methods
Cell culture and transfection. HFFs (Viromed Laboratories) were grown in Dulbecco’s Modified Eagle’s 
medium (DMEM) supplemented with 10% fetal calf serum (FCS), 100 U/ml of penicillin, 100 µg/ml of strepto-
mycin and 2 mM of L-glutamine at 37 °C and 5% CO2. WT MEFs, Mfn-null MEFs (Mfn1 −/−, Mfn2 −/−)40, and 
PACS-2-null (PACS-2 −/−) MEFs39 were cultured in DMEM supplemented with 10% FCS, 100 U/ml of penicil-
lin and 100 µg/ml of streptomycin; whereas, Drp1-null MEFs (Drp1 −/−)41 were cultured in Iscove’s Modified 
Dulbecco’s Medium (IMDM) supplemented with 10% FCS, 100 U/ml of penicillin and 100 µg/ml streptomycin.
HFFs and MEFs were plated on 18 mm (for confocal microscopy) or 25 mm (for MSIM) cover slips and trans-
fected one day later using Lipofectamine 2000 (Life Technologies) as previously described36. Plasmids encoding 
vMIA-EGFP55, vMIA-CFP11, mouse Tom20 (Tom20)-YFP56, PACS-2-EGFP18, mCherry-Drp157, Mfn2-YFP48, 
Tom20-mCherry, or vMIA-mCherry were used for transfection. Monomeric EGFP expression vector (Clontech 
Laboratories, Madison WI) was used as a control.
Tom20-mCherry expression plasmid was generated by sub-cloning of the mouse Tom20 cDNA upstream 
of the mCherry open reading frame in mCherry N-1 vector (Clontech Laboratories). The vMIA open reading 
frame was analogously sub-cloned into pmCherry N-1. The plasmid sequence was confirmed using a commercial 
sequencing company (Macrogen).
PACS-2 siRNAs. PACS-2 siRNAs18 were used as described to reduce PACS-2 expression and destabi-
lize ER-mitochondria contacts. A nonspecific random siRNA (5′-CGUUUGCGGUGUUUAUGGCtt-3′; 
5′-GCCAUAAACACCGCAAACGtt-3′) was used as a control. BLASTN searches with the nonspecific siRNA 
detected no significant similarity in the human genome database (A. Colberg-Poley, unpublished results). Briefly, 
HeLa cells expressing EGFP tagged human phosphatidylserine synthase 1, named PSS-120 cells8, were transfected 
with 7 μg of vMIA expression vector and 100 nM of PACS-2 siRNAs (Dharmacon) or 100 nM of nonspecific siR-
NAs (Ambion).
Fractionation of mitochondria and microsomes. Mitochondria and microsomes were isolated from 
transfected PSS-120 cells as described8,58. Briefly, cells were washed twice in PBS and pelleted by centrifuga-
tion, resuspended and lysed using a motor-driven Potter-Elvehjem homogenizer. The supernatant from pel-
leted homogenates was then centrifuged at 10,300 × g to separate microsomal (microsomes and cytosol) from 
crude mitochondrial (MAM and mitochondria) fraction. Microsomes were pelleted by ultracentrifugation 
at 100,000 × g from the crude microsomal fraction (supernatant). Mitochondria fractions were separated in 
self-generating Percoll gradients. Isolated fractions were diluted fivefold in sucrose homogenization medium and 
subjected separately to a centrifugation at 6,300 × g for 10 min at 4 °C. The pellet of the mitochondria centrifu-
gation was used as the purified mitochondria in our analysis. All of the fractions were resuspended in sucrose 
homogenization medium and analyzed by Western blot analysis.
Confocal microscopy and analysis. Confocal images were acquired on Olympus FV 1000 and Leica TCS 
SP8 microscopes. On the Leica TCS SP8, a HC PL APO CS2 100x/1.40 Oil objective was used to acquire images. 
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514 nm and 633 nm laser lines from a White Light Laser was used to excite YFP and Alexa 647 fluorophores. 
The emission was collected on hybrid detectors with the AOBS set to 520–610 nm and 640–750 nm respectively. 
These images were deconvolved using the Huygens software (Scientific Volume Imaging). On the Olympus FV 
1000, UPlanSApo 100 X/1.40 NA oil objective was used to acquire 1024 × 1024 pixels image, where each pixel 
was 62 nm in size. A step size of 410 nm was used for the z-stacks. For images that were to be deconvolved, step 
size of 110 nm was used for acquiring the z-stacks. 440 nm, 488 nm, 515 nm and 559 nm lasers were used to excite 
CFP, GFP, YFP and mCherry fluorophores, respectively. For triple color (CFP-YFP-mCherry) imaging 405 nm 
laser was used to excite CFP and emission collected with (425–475 nm filter), which prevented any excitation or 
emission bleedthrough and optimal excitation of YFP and mCherry. The image analysis was carried out using 
Olympus Fluoview version 4.0, MetaMorph Premier and Fiji ImageJ software. For image deconvolution CellSens 
Dimension software version 1.12 (Olympus Life Science) was used. Constrained iterative 3-D deconvolution 
module with the advanced maximum likelihood estimation algorithm (ADVMLE) was employed. The plots used 
to identify clustering on the deconvolved images were made using MetaMorph Premier (7.7.0) software, which 
was provided by Molecular Devices, LLC. For pixel colocalization analysis the individual channels of the confocal 
images were separated and the average intensity of pixels within the selection was calculated. The resulting value 
of 0.9 X average intensity was used to threshold the channel. Integrated morphometry analysis (IMA) module of 
the MetaMorph Premier 7.0 software was used to identify objects in the image larger than 0.14 µm2 to generate 
the mask for use in colocalization analysis.
Gated Stimulated Emission Depletion Microscopy (GSTED). STED imaging was done using the 
Leica TCS SP8 equipped with a White Light Laser, two depletion lasers and hybrid detectors. A HC PL APO CS2 
100x/1.40 Oil objective was used to acquire 12-bit images with pixel size less than 25 nm. The Tom20-Alexa 647 
was excited at 633 nm and depleted with 775 nm laser. The emission was collected between 640 nm to 750 nm with 
a time gating of 0.3 ns to 6.0 ns. Sequential stack for vMIA-YFP, using a 514 nm excitation and 660 nm depletion, 
was acquired from 520 nm to 610 nm and time-gated between 1.5 ns and 6.0 ns. Z-stacks with a step size of 170 nm 
or less was acquired and deconvolved using the Huygens Professional software (Scientific Volume Imaging).
MSIM Sample Preparation and Imaging. At 16 to 24 hours post-transfection, cells were fixed using 4% 
paraformaldehyde (PFA) (Electron Microscopy Sciences) in PBS, pre-warmed to 37 °C, for 15 minutes at room 
temperature. After fixation cells were washed with PBS and coverslips were mounted with ProLong Diamond 
Antifade Reagent (Life Technologies) onto slides and left overnight to dry at room temperature. For MSIM imag-
ing, tetraspecs (Thermo Fisher) were added onto 25 mm coverslips that contained cells with multiple fluorophores 
prior to mounting onto another 25 mm coverslip with ProLong Diamond Antifade Reagent and left to dry over-
night at room temperature.
The MSIM microscope used for these experiments is made from an Olympus IX-71 widefield microscope 
as previously described36. Briefly, critical modifications made to provide an increase its resolution capabilities 
include placing a microlens array in the illumination pathway to provide a two-dimensional pattern of excita-
tion spots within the focus of the objective lens. This pattern was translated in approximately 1 pixel size steps 
over the field of view while collecting an image at each position. Images were taken in z-stacks with 200 images 
taken per plane for each fluorophore used. MSIM processing was performed using code written in Python and 
provided by the Hari Shroff lab at the NIH59. After processing, the resulting images were a widefield image, and 
deconvolution of the widefield, and the MSIM image. MSIM images taken were 512 × 512 pixels; however, during 
processing, images were scaled up to 1024 × 1024 pixels. Any further processing of the MSIM images was done in 
ImageJ (NIH). Light sources used to excite fluorophores within cells were a 50 mW 488 laser to illuminate green 
fluorophores and a 50 mW 561 Sapphire laser to illuminate red fluorophores. All settings for the microscope were 
controlled using Micro-Manager. A 100 × 1.4 NA Nikon oil immersion objective was used for imaging in these 
experiments.
FLIM. The frequency domain FLIM analysis was performed with live cells roughly 20 hours after transfec-
tion. An Olympus BX81 inverted microscope was used to acquire widefield FLIM images. All the images were 
acquired using a UApoN 100 X/1.49 oil objective. A 488 nm laser (Intelligent Imaging Innovations) modulated at 
50 MHz was used to excite the fluorophores in the samples. The fluorescence lifetime signal was measured using 
the II18MD modulated image intensifier (Lambert Instruments). The modulation was set to 0.23 and the inten-
sification was set to 2,500. A CoolSNAP EZ camera (Photometrics) was used to acquire phase-shifted images. 
Rhodamine 101 (Sigma-Aldrich) dissolved in water, with a lifetime of 4.32 ns, was used to calibrate the system. 
It was also used to check the stability of the system over the course of the experiment. Images from 10–15 fields 
of view were collected for each sample type. At least 10 regions of interest (ROI) were marked randomly on each 
cell. The fluorescence lifetime from these ROIs were analyzed. The image acquisition and analysis was done using 
Slidebook version 6 software from Intelligent Imaging Innovations. The lifetime of individual pixels was calcu-
lated using the polar plot representation for the frequency-domain fluorescence lifetime data60.
Statistical analysis. The methods for data acquisition and the sample sizes used are described for each 
individual experiment. Quantitative data are expressed as the mean value (mean ± standard error of the mean 
(SEM)). Statistical analysis of all the experimental data was performed using GraphPad Prism 5 software. Each 
set of values were tested for normality to choose appropriate statistical analysis. The values for vMIA mutant clus-
ter sizes (WT and CBDII) and for vMIA colocalization with mitochondria were normally distributed and thus 
two-tailed unpaired t test was used for p-value measurements. For all the other analyses the data were tested using 
two-tailed Mann-Whitney U t-test.
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